Vantage logo

Covid-19 divides the biggest medtechs

Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.

Vantage logo

Legend joins the billion-dollar club

With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.

Vantage logo

Covid-19 stalls biotech flotations

Several young drug developers managed to float in the first quarter, but new issues dried up in March when coronavirus infected the markets. Is the game back on?